中国儿童保健杂志 ›› 2011, Vol. 19 ›› Issue (11): 1033-1035.

• 临床研究与分析 • 上一篇    下一篇

沙美特罗替卡松粉吸入剂治疗中、重度儿童哮喘的临床疗效观察

马彩玲,段波,田玉珍   

  1. 西安市儿童医院,陕西 西安 710002
  • 收稿日期:2011-06-17 发布日期:2011-11-06 出版日期:2011-11-06
  • 作者简介:马彩玲(1963-),女,陕西人,副主任医师,本科学历,主要研究方向为小儿呼吸系统疾病

Analysis of therapeutic effect of salmeterol/fluticasone on moderate and severe children asthma treated by inhalation

MA Cai-ling,DUAN Bo,TIAN Yu-zhen   

  1. Xi'an Children's Hospital,Xi'an Shaanxi 710002,China
  • Received:2011-06-17 Online:2011-11-06 Published:2011-11-06

摘要: 【目的】 了解沙美特罗替卡松粉吸入剂(商品名:舒利迭)治疗中、重度儿童哮喘的临床治疗效果。 【方法】 收集了2009年1月-2010年3月本院哮喘门诊及住院的中、重度哮喘患儿46例,分别于吸入舒利迭治疗前及治疗3个月后,做肺通气功能及评价患儿临床控制情况。 【结果】 1)治疗3个月后肺通气功能明显改善:FEV1、PEF、FEF25、FEF50、FEF75、MMEF75/25治疗前分别为(1.31±0.59)、(3.05±1.33)、(2.39±1.17)、(1.30±0.69)、(0.52±0.28)、(1.08±0.60) L/S, 吸入舒利迭治疗3个月后分别为(1.90±0.59)、(4.45±1.35)、(3.80±1.17)、(2.34±0.80)、(0.98±0.39)、(2.10±0.82) L/S(治疗前、后比较t值依次为4.80、5.02、5.78、6.67、6.57、6.80;P均<0.001);其中28例(60.9%)肺通气功能恢复正常,一项异常7例(15.2%),2项异常4例(8.7%),3项异常5例(10.9%),4项和5项异常各1例(2.2%),6项均异常0例;2)吸入舒利迭治疗3个月后87%(40例)的患儿达到临床控制,8.7%(4例)的患儿部分控制,4.3%(2例)未控制。 【结论】 吸入舒利迭可显著改善中、重度儿童哮喘临床症状及肺通气功能,是治疗年长儿童中、重度哮喘较为理想的药物,值得临床推广应用。

关键词: 沙美特罗替卡松粉吸入剂, 治疗, 儿童, 哮喘

Abstract: 【Objective】 To observe the efficacy of salmeterol/fluticasone(commodity name:Seretide) in the treatment of children with moderate and severe asthma. 【Method】 Evaluate the efficacy by lung ventilation function and clinical asthma control of the 46 moderate and severe asthmatic cases from our outpatient department and the hospital during January 2009 and March 2010 treated by Seretide. 【Results】 1)Significant improvement on the lung ventilation function was founded after 3 months treatment by Seretide. Before the treatment:FEV1、PEF,FEF25 ,FEF50,FEF75,MMEF75/25were (1.31±0.59),(3.05±1.33),(2.39±1.17),(1.30±0.69),(0.52±0.28),(1.08±0.60) L/S;after 3 months treatment, FEV1,PEF,FEF25,FEF50,FEF75,MMEF75/25 were (1.90±0.59),(4.45±1.35),(3.80±1.17),(2.34±0.80),(0.98±0.39),(2.10±0.82) L/S(t=4.80,5.02,5.78,6.67,6.57,6.80;all P<0.001);of which 28 patients (60.9%) lung ventilation function returns to normal, a abnormal 7 cases (15.2%), two anomalies in 4 (8.7%) ,3 of abnormal in 5 patients (10.9%), four and five abnormal each 1 cases (2.2%), and six indexes abnormal 0); 2)87%(40 cases )of children were clinical controlled , 8.7% (4 cases)of children were partially controlled, 4.3% (2 cases)were not controlled. 【Conclusions】 Seretide can significantly improve moderate and severe children asthma clinical symptoms, lung ventilation function. So, it is an ideal treatment of the older children, moderate and severe asthma, to be worth of clinical application.

Key words: salmeterol/fluticasone, treatment, children, asthma

中图分类号: